Table 4. Haplotype analysis of rs3077, rs9277535 and rs7453920 with HBV susceptibility, seroclearance and HCC development.

Haplotype	case(freq)	control(freq)	OR	95%CI	p value
(A)
AAA	24 (0.029)	20 (0.042)	0.66	0.36–1.22	0.183
AAG	132 (0.158)	97 (0.208)	0.7	0.52–0.94	0.016
AGG	71 (0.085)	37 (0.080)	1.05	0.69–1.59	0.811
GAG	67 (0.080)	65 (0.139)	0.53	0.37–0.77	0.0006
GGG	511 (0.661)	224 (0.481)	1.69	1.34–2.14	1.10E-05
(B)
AAG	132 (0.158)	129 (0.178)	0.83	0.64–1.08	0.174
AGG	71 (0.085)	69 (0.096)	0.85	0.60–1.20	0.346
GAG	67 (0.080)	95 (0.131)	0.56	0.40–0.77	0.0004
GGA	25 (0.029)	22 (0.031)	0.92	0.51–1.64	0.769
GGG	511 (0.611)	348 (0.480)	1.6	1.31–1.96	5.91E-06
(C)
AAG	77 (0.175)	132 (0.158)	1.1	0.81–1.50	0.55
AGG	28 (0.063)	71 (0.085)	0.71	0.45–1.12	0.136
GAG	37 (0.083)	67 (0.080)	1.02	0.67–1.55	0.942
GGG	280 (0.634)	511 (0.611)	1.04	0.81–1.34	0.732

(A) Haplotype analysis on HBV susceptibility; (B) Haplotype analysis on HBV seroclearance; (C) Haplotype analysis on HCC development.